ArticleBMC medicine2021
Potential impact of individual exposure histories to endemic human coronaviruses on age-dependent severity of COVID-19.
Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Antibody Responses to SARS-CoV-2 and Common HCoVs in Hemodialysis Patients and Transplant Recipients: Data from the Dominican Republic.Vaccines · 2025Article
- Darwin review: the evolution of virulence in human pathogens.Proceedings. Biological sciences · 2024Review
- COVID-19 vaccination survey and anti-SARS-CoV-2 IgG responses in a human cohort fromFrontiers in public health · 2024Article
- Immune imprinting and next-generation coronavirus vaccines.Nature microbiology · 2023Review
- Natural selection of immune and metabolic genes associated with health in two lowland Bolivian populations.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Using simulation modelling and systems science to help contain COVID-19: A systematic review.Systems research and behavioral science · 2022Article
- Simulating the efficacy of vaccines on the epidemiological dynamics of SARS-CoV-2 in a membrane computing model.microLife · 2022Article
- The impact of cross-reactive immunity on the emergence of SARS-CoV-2 variants.Frontiers in immunology · 2022Article
- How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.Science immunology · 2021Article
- Multi-Subunit SARS-CoV-2 Vaccine Design Using Evolutionarily Conserved T- and B- Cell Epitopes.Vaccines · 2021Article
- Early cross-coronavirus reactive signatures of protective humoral immunity against COVID-19.bioRxiv : the preprint server for biology · 2021Article
- Moderate Red Wine Consumption Increases the Expression of Longevity-Associated Genes in Controlled Human Populations and Extends Lifespan inAntioxidants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundCross-reactivity to SARS-CoV-2 from exposure to endemic human coronaviruses (eHCoV) is gaining increasing attention as a possible driver of both protection against infection and COVID-19 severity. Here we explore the potential role of cross-reactivity induced by eHCoVs on age-specific COVID-19 severity in a mathematical model of eHCoV and SARS-CoV-2 transmission.
methodsWe use an individual-based model, calibrated to prior knowledge of eHCoV dynamics, to fully track individual histories of exposure to eHCoVs. We also model the emergent dynamics of SARS-CoV-2 and the risk of hospitalisation upon infection.
resultsWe hypothesise that primary exposure with any eHCoV confers temporary cross-protection against severe SARS-CoV-2 infection, while life-long re-exposure to the same eHCoV diminishes cross-protection, and increases the potential for disease severity. We show numerically that our proposed mechanism can explain age patterns of COVID-19 hospitalisation in EU/EEA countries and the UK. We further show that some of the observed variation in health care capacity and testing efforts is compatible with country-specific differences in hospitalisation rates under this model.
conclusionsThis study provides a "proof of possibility" for certain biological and epidemiological mechanisms that could potentially drive COVID-19-related variation across age groups. Our findings call for further research on the role of cross-reactivity to eHCoVs and highlight data interpretation challenges arising from health care capacity and SARS-CoV-2 testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.